Unicycive Therapeutics stock faces class action pressure after manufacturing oversight claims

Published on 09/18/2026 at 11:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Unicycive Therapeutics stock is under pressure as investor-rights firms highlight a September 17, 2026 securities class action over manufacturing oversight. The shares recently traded near USD 4.77 on Nasdaq on September 17, 2026, well below levels seen before a June 2026 drop.

UNCY, US90467V1098, Illustration mit AI erstellt.

Unicycive Therapeutics, Inc. stock (ISIN US90467V1098) has come into sharper focus for investors after several law firms announced a securities class action on September 17, 2026, alleging misleading disclosures around manufacturing oversight for its kidney drug candidate, while the Nasdaq-listed shares most recently closed around USD 4.77 on September 17, 2026.

Class action lawsuits highlight regulatory and disclosure risks

According to Kirby McInerney LLP on September 17, 2026, investors who acquired Unicycive Therapeutics securities between December 29, 2025 and June 29, 2026 have until November 2, 2026 to seek appointment as lead plaintiff in a pending federal securities class action.

As PR Newswire reported on September 17, 2026, a complaint alleges that Unicycive Therapeutics spent roughly six months telling shareholders its OLC (oxalate-lowering compound) new drug application with the US Food and Drug Administration was on track while failing to verify, through its own inspection, that the third-party manufacturer addressed deficiencies from a prior FDA rejection.

In a separate notice, WBOC relayed on September 17, 2026 that Bronstein, Gewirtz & Grossman LLC filed a class action on behalf of investors over the same December 29, 2025 to June 29, 2026 period, alleging that Unicycive Therapeutics had not inspected its third-party manufacturing vendor’s facility or audited compliance with current good manufacturing practices.

Stock performance and market reaction to June 2026 disclosure

As highlighted by PR Newswire, Unicycive Therapeutics shares closed at USD 7.70 on June 29, 2026, before dropping USD 3.01, or 39.1%, to USD 4.69 in the next trading session on unusually heavy volume after the company disclosed manufacturing-related issues affecting its regulatory timeline.

Per recent Nasdaq data referenced in an analyst overview on Yahoo Finance, Unicycive Therapeutics stock last traded around USD 4.77 at the close on September 17, 2026, implying that the shares remain roughly 38.1% below the USD 7.70 level seen at the end of the June 29, 2026 session.

The same overview shows that, relative to shorter-term performance metrics, Unicycive Therapeutics has experienced declines over one-week and one-month horizons, while longer-horizon figures like 52-week performance and three-year performance are markedly volatile, underscoring the high-risk profile typical of early-stage biotechnology companies.

Fundamental backdrop and investor considerations

The class action filings center on allegations that Unicycive Therapeutics misrepresented the state of its OLC manufacturing readiness during the Class Period, rather than on a newly reported earnings miss or revenue shortfall, so the immediate catalyst is legal and regulatory in nature rather than a fresh quarterly report.

While detailed quarterly revenue and earnings figures for Unicycive Therapeutics’ most recent reporting period are typically available via company filings on its investor relations site, such as the start page at Unicycive Therapeutics, the current newsflow emphasizes alleged disclosure shortcomings rather than operational metrics.

For investors, the most concrete quantitative reference in the current legal narrative is the price impact of the June 2026 disclosure: a one-session decline of USD 3.01 from USD 7.70 to USD 4.69, or 39.1%, which has effectively reset the trading range for Unicycive Therapeutics stock and remains central to the damage claims in the class actions.

Looking ahead from September 18, 2026, the scheduled lead-plaintiff deadline of November 2, 2026 for investors to step forward in the Kirby McInerney and Bronstein, Gewirtz & Grossman actions is an important calendar marker, and any future FDA feedback on the OLC program or company updates on manufacturing remediation could either mitigate or exacerbate perceived risk.

Unicycive Therapeutics stock stays near mid-single-digit levels

As of the close on September 17, 2026, Unicycive Therapeutics stock traded on Nasdaq around USD 4.77 in US dollars, keeping the shares near the mid-single-digit range that emerged after the 39.1% drop from USD 7.70 to USD 4.69 in late June 2026.